Medical Technology

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 3 years ago

Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

@xconomy.com 3 years ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 years ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 4 years ago

Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September

@xconomy.com 5 years ago

FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

@xconomy.com 5 years ago

Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests

@xconomy.com 5 years ago

Six Life Science Firms Close Q3 with an IPO, More Are on the Way

@xconomy.com 5 years ago

In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

@xconomy.com 5 years ago

With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines

@xconomy.com 5 years ago

CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”